# Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

> **NCT02015208** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 13 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02015208
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015208, "Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02015208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*